All In MedTech

FDA Clearance Tracker · P160036

Hintermann Series H3 Total Ankle Replacement System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jun 4, 2019 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 4, 2019

Approved

Time to decision

1,014 days

Received Aug 24, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P160036
Device name
Hintermann Series H3 Total Ankle Replacement System
Applicant location
Towson, MD
Received
Aug 24, 2016
Decided
Jun 4, 2019
Decision
Approved
Supplements
6 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NTG

FDA's approval statement

As written in FDA's record.

Approval for the Hintermann Series H3 Total Ankle Replacement System. The device is indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis or arthritis secondary to inflammatory disease (e.g. rheumatoid arthritis, hemochromatosis, etc.). The device system is for prescription use.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NTG. The earliest in FDA's data is P050050, decided May 27, 2009.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Dt Medtech, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.